Ironwood Pharmaceuticals (IRWD) : Sector Gamma As reduced its stake in Ironwood Pharmaceuticals by 28.85% during the most recent quarter end. The investment management company now holds a total of 1,769,368 shares of Ironwood Pharmaceuticals which is valued at $23,638,756 after selling 717,389 shares in Ironwood Pharmaceuticals , the firm said in a disclosure report filed with the SEC on Aug 11, 2016.Ironwood Pharmaceuticals makes up approximately 4.52% of Sector Gamma As’s portfolio.
Other Hedge Funds, Including , Engineers Gate Manager Lp added IRWD to its portfolio by purchasing 82,314 company shares during the most recent quarter which is valued at $1,099,715. Ironwood Pharmaceuticals makes up approx 0.07% of Engineers Gate Manager Lp’s portfolio.State Board Of Administration Of Florida Retirement System boosted its stake in IRWD in the latest quarter, The investment management firm added 663 additional shares and now holds a total of 88,066 shares of Ironwood Pharmaceuticals which is valued at $1,179,204.Diam Ltd. reduced its stake in IRWD by selling 36,719 shares or 4.39% in the most recent quarter. The Hedge Fund company now holds 799,751 shares of IRWD which is valued at $11,388,454. Ironwood Pharmaceuticals makes up approx 0.16% of Diam Ltd.’s portfolio. Quantitative Investment Management added IRWD to its portfolio by purchasing 72,500 company shares during the most recent quarter which is valued at $1,032,400. Ironwood Pharmaceuticals makes up approx 0.05% of Quantitative Investment Management’s portfolio.
Ironwood Pharmaceuticals opened for trading at $13.85 and hit $14 on the upside on Tuesday, eventually ending the session at $13.97, with a gain of 1.23% or 0.17 points. The heightened volatility saw the trading volume jump to 9,69,790 shares. Company has a market cap of $2,030 M.
On the company’s financial health, Ironwood Pharmaceuticals reported $-0.16 EPS for the quarter, based on the information available during the earnings call on Aug 4, 2016. Analyst had a consensus estimate of $-0.16. The company had revenue of $54.40 million for the quarter, compared to analysts expectations of $54.49 million. The company’s revenue was up 96.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.34 EPS.
Many Wall Street Analysts have commented on Ironwood Pharmaceuticals. Company shares were Reiterated by Mizuho on Jul 15, 2016 to “Buy”, Firm has raised the Price Target to $ 24 from a previous price target of $16 .
Ironwood Pharmaceuticals Inc. is a pharmaceutical company. The Company has a product linaclotide which is available in the United States and Mexico under the brand name LINZESS and is available in European countries and Canada under the brand name CONSTELLA. Linaclotide is also being developed and commercialized in other parts of the world by certain of its partners. Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. The Company in collaboration with Astellas Pharma Inc. (Astellas) is developing linaclotide for the treatment of patients with IBS-C.